Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

SEATTLE GENETICS, INC.

(SGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2020 05/26/2020 05/27/2020 05/28/2020 05/29/2020 Date
155.77(c) 151.73(c) 152.97(c) 151.55(c) 157.21(c) Last
1 102 573 3 425 177 2 084 098 1 137 152 1 679 880 Volume
+1.01% -2.59% +0.82% -0.93% +3.73% Change
More quotes
Financials (USD)
Sales 2020 1 077 M - -
Net income 2020 -481 M - -
Net cash position 2020 502 M - -
P/E ratio 2020 -56,5x
Yield 2020 -
Sales 2021 1 585 M - -
Net income 2021 -132 M - -
Net cash position 2021 578 M - -
P/E ratio 2021 -230x
Yield 2021 -
Capitalization 27 213 M 27 213 M -
EV / Sales 2020 24,8x
EV / Sales 2021 16,8x
Nbr of Employees 1 605
Free-Float 99,3%
More Financials
Company
Seattle Genetics, Inc. specialises in the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. Net sales break down by source of income as follows: - sales of products (68.5%); - sales from licensing and collaboration agreements (16.4%); - royalties (15.1%).  
More about the company
Surperformance© ratings of Seattle Genetics, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SEATTLE GENETICS, INC.
05/29SEATTLE GENETICS : Announces Positive Results from Exploratory Analyses of HER2C..
BU
05/19SEATTLE GENETICS INC /WA : Submission of Matters to a Vote of Security Holders (..
AQ
05/18SEATTLE GENETICS : Antibody-Drug Conjugate Innovation and Targeted Therapy Progr..
BU
05/15TAKEDA PHARMACEUTICAL : European Commission Approves ADCETRIS for Treatment of A..
AQ
05/14SEATTLE GENETICS : Announces ADCETRIS® (Brentuximab Vedotin) Receives European C..
BU
05/13SEATTLE GENETICS : Highlights Data from Expanding Oncology Portfolio During Virt..
BU
05/13SEATTLE GENETICS : Announces the Approval of TUKYSA in Switzerland for the Treat..
AQ
05/12SEATTLE GENETICS : Announces the Approval of TUKYSA™ (tucatinib) in Switze..
BU
05/05SEATTLE GENETICS : to Present at the BofA Securities Virtual Health Care Confere..
BU
04/30SEATTLE GENETICS : WA Management's Discussion and Analysis of Financial Conditio..
AQ
04/30SEATTLE GENETICS : 1Q Earnings Snapshot
AQ
04/30SEATTLE GENETICS INC /WA : Results of Operations and Financial Condition (form 8..
AQ
04/30SEATTLE GENETICS : Reports First Quarter 2020 Financial Results
BU
04/24SEATTLE GENETICS : Announces Change to Virtual Format for 2020 Annual Meeting
BU
04/21SEATTLE GENETICS : TUKYSA, FDA Approved for Treatment of Advanced Unresectable o..
AQ
More news
News in other languages on SEATTLE GENETICS, INC.
05/29SEATTLE GENETICS : Announces Positive Results from Exploratory Analyses of HER2C..
05/19SEATTLE GENETICS INC /WA : Submission of Matters to a Vote of Security Holders (..
05/18SEATTLE GENETICS : Antibody-Drug Conjugate Innovation and Targeted Therapy Progr..
05/15TAKEDA PHARMACEUTICAL : European Commission Approves ADCETRIS for Treatment of A..
05/14SEATTLE GENETICS : Announces ADCETRIS® (Brentuximab Vedotin) Receives European C..
More news
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEATTLE GENETICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 156,05 $
Last Close Price 157,21 $
Spread / Highest target 56,5%
Spread / Average Target -0,74%
Spread / Lowest Target -39,6%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Robert J. Lechleider Senior Vice President-Clinical Development
Roger D. Dansey Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.37.59%27 213
LONZA GROUP33.49%36 433
IQVIA HOLDINGS INC.-3.23%28 553
MODERNA, INC.214.42%23 913
CELLTRION, INC.17.96%23 085
INCYTE CORPORATION15.15%22 153